Avenue Therapeutics(ATXI) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024 warrant exercise transaction - Miami, FL – August 9, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the develo ...